Your browser doesn't support javascript.
loading
Biology of Interleukin-17 and Novel Therapies for Hidradenitis Suppurativa.
Sabat, Robert; Gudjonsson, Johann Eli; Brembilla, Nicolo Costantino; van Straalen, Kelsey R; Wolk, Kerstin.
Afiliação
  • Sabat R; Psoriasis Research and Treatment Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Gudjonsson JE; Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA.
  • Brembilla NC; Taubman Medical Research Institute, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • van Straalen KR; Division of Dermatology and Venereology, Geneva University Hospitals, Geneva, Switzerland.
  • Wolk K; Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
J Interferon Cytokine Res ; 43(12): 544-556, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37824200
ABSTRACT
Skin disorders affect ∼40% of the human population. One of the most debilitating cutaneous disorders is Hidradenitis suppurativa (HS), a noncommunicable chronic inflammatory disease with an estimated global prevalence of 0.4% to 2.5%. In January 2011, high levels of IL-17 were discovered in skin lesions of HS patients. In the following years, translational and clinical research led to a better understanding of the pathogenesis of HS. In June 2023, more than 12 years after the initial note, secukinumab, an anti-IL-17A monoclonal antibody, was approved for the treatment of moderate to severe HS. This is the next milestone in improving the treatment of these patients after the approval of the anti-TNF-α monoclonal antibody adalimumab in 2015. In this review article, we present the IL-17 pathway in HS and discuss the use of secukinumab as a therapeutic option for this disease. Our review starts with a description of the epidemiology, clinical features, etiology, and pathogenesis of HS. An overview of the IL-17/IL-17 receptor system in general and a detailed description of the known facts about the expression and action of IL-17 in HS follow. Afterward, we consider the results of clinical trials evaluating the safety and efficacy of IL-17 inhibitors in HS. Finally, a comparison is made between secukinumab and adalimumab and the characteristics of the patients that may be particularly suitable for each of these biologics are described.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hidradenite Supurativa Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hidradenite Supurativa Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article